Evidence map›Paper›PMID 41124303›Full record

ArticleJournal of neuromuscular diseases2026

Dermatomyositis masking late onset Pompe disease in a patient with proximal muscle weakness.

Omar Keritam, Philipp Haas, Sigrid Klotz, Kastriot Kastrati, Martin Krenn, Matias Wagner, Timothy Hasenoehrl, Rosa Weng, Gudrun Zulehner, Gregor Kasprian and 7 more

Abstract readCase Reports
In one paragraph

Article in Journal of neuromuscular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Omar KeritamDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Philipp HaasComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Sigrid KlotzComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Kastriot KastratiDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Martin KrennDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Matias WagnerInstitute of Neurogenomics, Helmholtz Centrum, Munich, Germany.
Timothy HasenoehrlDepartment of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria.
Rosa WengDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Gudrun ZulehnerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Gregor KasprianComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Günther RegelsbergerComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Hans KienerDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Ellen GelpiComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Fritz ZimprichDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Hakan CetinDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Thomas SchererDepartment of Medicine III, Division of Endocrinology, Medical University of Vienna, Vienna, Austria.
Suren JengojanComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Slowly progressive proximal muscle weakness in an otherwise healthy male posed particular challenges for the treating physicians, considering the wide range of possible differentials. Here we present a case of a 52-year-old male with paraparesis, elevated creatine kinase-levels, antibodies against the Mi-2 antigen and subtle skin lesions, leading to subsequent treatment for dermatomyositis. Beyond that, exome sequencing revealed biallelic variants in the gene encoding acid alpha-glucosidase with concordant reduced enzymatic activity in fibroblasts, indicating late onset Pompe disease. Subsequently performed magnetic resonance imaging revealed a pattern of involvement typical for LOPD, but histological workup from the vastus lateralis muscle was more indicative of an immune-mediated myopathy. After treatment for dermatomyositis and Pompe disease the patient showed an improvement in skin changes and a halt in muscular weakness. In conclusion, both entities could be seen in the patient. However, early and prolonged subclinical hyper-CK-emia hinted at Pompe disease as the primary entity.

Indexed as

DermatomyositisGlycogen Storage Disease Type IIMuscle WeaknessAge of Onsetalpha-GlucosidasesDiagnosis, DifferentialHumansMaleMiddle Agedalpha-Glucosidasescase reportdermatomyositisinflammatory myopathylate onset Pompe disease

Identifiers

PMID41124303
PMCPMC13434907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.